Northern Trust Corp Reduces Position in AMNEAL PHARMACEUTICALS, INC. $AMRX

Key Points

• Northern Trust Corp reduced its stake in AMNEAL PHARMACEUTICALS by 3.9% to approximately $14.32 million, holding 1,708,627 shares at the end of the quarter.
• AMNEAL PHARMACEUTICALS reported $0.23 EPS for the quarter, surpassing analysts' expectations of $0.17, while setting FY 2025 guidance at 0.700-0.750 EPS.
• Analysts have a consensus rating of "Buy"** on AMNEAL PHARMACEUTICALS, with a price target averaging $11.60.

Northern Trust Corp lowered its stake in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Free Report) by 3.9% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,708,627 shares of the company's stock after selling 68,656 shares during the quarter. Northern Trust Corp owned 0.55% of AMNEAL PHARMACEUTICALS worth $14,318,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of AMRX. Hsbc Holdings PLC boosted its holdings in AMNEAL PHARMACEUTICALS by 29.7% during the 4th quarter. Hsbc Holdings PLC now owns 60,061 shares of the company's stock worth $476,000 after acquiring an additional 13,757 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in AMNEAL PHARMACEUTICALS by 11.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 97,250 shares of the company's stock worth $771,000 after acquiring an additional 9,704 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in AMNEAL PHARMACEUTICALS by 209.2% during the 4th quarter. BNP Paribas Financial Markets now owns 168,194 shares of the company's stock worth $1,332,000 after acquiring an additional 113,796 shares during the last quarter. Bank of America Corp DE boosted its holdings in AMNEAL PHARMACEUTICALS by 218.8% during the 4th quarter. Bank of America Corp DE now owns 556,881 shares of the company's stock worth $4,410,000 after acquiring an additional 382,222 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in AMNEAL PHARMACEUTICALS during the 4th quarter worth $1,365,000. Institutional investors own 31.82% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on AMRX shares. The Goldman Sachs Group assumed coverage on shares of AMNEAL PHARMACEUTICALS in a report on Friday, June 6th. They set a "buy" rating and a $12.00 price objective on the stock. Wall Street Zen downgraded shares of AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, AMNEAL PHARMACEUTICALS currently has a consensus rating of "Buy" and an average price target of $11.60.

Insider Activity at AMNEAL PHARMACEUTICALS

In related news, EVP Nikita Shah sold 114,492 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $9.66, for a total value of $1,105,992.72. Following the transaction, the executive vice president directly owned 152,743 shares in the company, valued at approximately $1,475,497.38. This represents a 42.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John Kiely sold 32,000 shares of the company's stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $9.23, for a total value of $295,360.00. Following the completion of the sale, the director directly owned 225,433 shares of the company's stock, valued at approximately $2,080,746.59. This represents a 12.43% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 609,206 shares of company stock valued at $5,700,625 in the last ninety days. 17.45% of the stock is currently owned by company insiders.

AMNEAL PHARMACEUTICALS Price Performance

Shares of AMRX traded down $0.09 during midday trading on Tuesday, hitting $9.65. 168,669 shares of the company traded hands, compared to its average volume of 1,663,267. The stock has a 50-day moving average of $8.71 and a 200-day moving average of $8.14. AMNEAL PHARMACEUTICALS, INC. has a one year low of $6.68 and a one year high of $9.80. The firm has a market cap of $3.03 billion, a P/E ratio of 965.47 and a beta of 1.19.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a net margin of 0.12% and a negative return on equity of 189.49%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. Sell-side analysts forecast that AMNEAL PHARMACEUTICALS, INC. will post 0.53 EPS for the current fiscal year.

AMNEAL PHARMACEUTICALS Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.